These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Recent advances in the treatment of advanced colorectal cancer. Kemeny N; Lokich JJ; Anderson N; Ahlgren JD Cancer; 1993 Jan; 71(1):9-18. PubMed ID: 8416731 [TBL] [Abstract][Full Text] [Related]
4. Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. Johnston PG; Benson AB; Catalano P; Rao MS; O'Dwyer PJ; Allegra CJ J Clin Oncol; 2003 Mar; 21(5):815-9. PubMed ID: 12610179 [TBL] [Abstract][Full Text] [Related]
5. The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer. Köhne CH; Wilke H; Schöffski P; Schmoll HJ J Infus Chemother; 1996; 6(4):206-10. PubMed ID: 9229317 [No Abstract] [Full Text] [Related]
6. Biochemical modulation of 5-fluorouracil by PALA. O'Dwyer PJ Cancer Invest; 1990; 8(2):261-2. PubMed ID: 2400945 [No Abstract] [Full Text] [Related]
7. Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials. Köhne-Wömpner CH; Schmoll HJ; Harstrick A; Rustum YM Semin Oncol; 1992 Apr; 19(2 Suppl 3):105-25. PubMed ID: 1373004 [TBL] [Abstract][Full Text] [Related]
8. How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer. Ragnhammar P; Blomgren H Med Oncol; 1995 Sep; 12(3):187-201. PubMed ID: 8852401 [No Abstract] [Full Text] [Related]
9. Sparfosate. A novel biomodulator of 5-fluorouracil. Koshland P; Maa L; Ignoffo R Cancer Pract; 1999; 7(4):212-6. PubMed ID: 10687588 [No Abstract] [Full Text] [Related]
10. Biochemical modulation: a modality that has come of therapeutic age. Allegra CJ J Clin Oncol; 1991 Oct; 9(10):1723-6. PubMed ID: 1919622 [No Abstract] [Full Text] [Related]
11. Chemotherapy of advanced cancer of the colon and rectum. Bruckner HW; Motwani BT Semin Oncol; 1991 Oct; 18(5):443-61. PubMed ID: 1925632 [No Abstract] [Full Text] [Related]
12. Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer. Kemeny N; Schneider A; Martin DS; Colofiore J; Sawyer RC; Derby S; Salvia B Cancer Res; 1989 Aug; 49(16):4636-9. PubMed ID: 2472883 [TBL] [Abstract][Full Text] [Related]
13. Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity. Kemeny NE; Schneider A; Martin DS Cancer Invest; 1990; 8(2):263-4. PubMed ID: 2400946 [No Abstract] [Full Text] [Related]
14. Biochemical modulation: application of laboratory models to the clinic. Leyland-Jones B; O'Dwyer PJ Cancer Treat Rep; 1986 Jan; 70(1):219-29. PubMed ID: 3510736 [No Abstract] [Full Text] [Related]
15. Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases. Leonard GD; Kemeny NE Dis Colon Rectum; 2006 Mar; 49(3):407-10. PubMed ID: 16475032 [TBL] [Abstract][Full Text] [Related]
16. The pharmacologic modulation of 5-fluorouracil with folinic acid, methotrexate, trimetrexate, and n-phosphonacetyl-l-aspartic acid (PALA). Mechanisms of the interactions and clinical data. Machover D Bull Cancer; 1994 Dec; 81 Suppl 2():74s-77s. PubMed ID: 7727863 [No Abstract] [Full Text] [Related]
17. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cao S; Rustum YM; Spector T Cancer Res; 1994 Mar; 54(6):1507-10. PubMed ID: 8137256 [TBL] [Abstract][Full Text] [Related]
18. Overview of N-(phosphonacetyl)-L-aspartate + fluorouracil in clinical trials. Martin DS; Kemeny NE Semin Oncol; 1992 Apr; 19(2 Suppl 3):228-33. PubMed ID: 1557654 [TBL] [Abstract][Full Text] [Related]
19. [The biochemical modulation of 5-fluorouracil by leucovorin]. Borner M; Brunner K Schweiz Med Wochenschr; 1991 Aug; 121(33):1149-56. PubMed ID: 1925442 [TBL] [Abstract][Full Text] [Related]
20. Biochemical modulation as an approach to reversal of antimetabolite resistance. O'Dwyer PJ Cancer Treat Res; 1994; 73():201-16. PubMed ID: 7536018 [No Abstract] [Full Text] [Related] [Next] [New Search]